Business
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism Cash Position of $522.1 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pion
About this update from Septerna, Inc.
[{"type":"image","alt":"Septerna, Inc.","displaySize":"","headline":null,"caption":"Septerna, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/d2f80cf1ee51689cfd5290865894d732"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vxaeungErl.ZjPyF4.bcBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4/https://media.zenfs.com/en/globenewswire.com/d2f80cf1ee51689cfd5290865894d732","width":300,"height":63},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/vxaeungErl.ZjPyF4.bcBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4/https://media.zenfs.com/en/globenewswire.com/d2f80cf1ee51689cfd5290865894d732","width":300,"height":63}},"lazy":false},{"type":"text","content":" Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 ","length":173,"tagName":"p"},{"type":"text","content":"Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism","length":102,"tagName":"p"},{"type":"text","content":"Cash Position of $522.1 Million Expected to Support Operating Plans at Least into 2029","length":86,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the first quarter ended March 31, 2026. ","length":344,"tagName":"p"},{"type":"text","content":"“In the first quarter, we continued to make meaningful progress across our pipeline, highlighted by positive Phase 1 clinical results for SEP-631 and the initiation of our Phase 1 clinical trial for SEP-479,” said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna. “These advances further validate our Native Complex Platform® and its ability to efficiently generate differentiated oral small molecules against historically challenging GPCR targets. As our clinical programs continue to advance, we believe Septerna is increasingly well positioned to unlock the broad therapeutic potential of GPCR-targeted medicines for patients with significant unmet need.”","length":688,"tagNa...